Compare Adaptive Biotechnologies Corp (ADPT) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Flux Power Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Flux Power Holdings Inc trades at $0.73 (market cap $16.02M). The key difference: Adaptive Biotechnologies Corp is far larger — about 207.9× Flux Power Holdings Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | FLUX | |
|---|---|---|
Market Cap | $3.33B | $16.02M |
Sector | Health | Utilities |
52-Week High | $22.37 | $6.66 |
52-Week Low | $10.24 | $0.75 |
Enterprise Value | $3.19B | $22.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FLUX trades at $0.8199, down 8.75% over 24 hours. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $6.67 million in 2025 with a negative net margin of 12.48%, while revenue declined to $51 million in 2026. Recent developments include the launch of SkyEMS 3.0 AI software and new executive appointments aimed at growth.
Outlook remains speculative with unanimous analyst buy ratings contrasting weak profitability. Key opportunities lie in software innovation and market expansion, but risks include persistent losses, revenue volatility, and intense clean energy competition. The stock's appeal hinges on execution turning losses to profits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
